What can nanosafety learn from drug development? The feasibility of “safety by design”

References

• Ahuja V, Sharma S. 2014. Drug safety testing paradigm, current progress and future challenges: an overview. J Appl Toxicol 34:576–94.
   PubMed Web of Science ®Google Scholar
• Blomme EAG, Will Y. 2016. Toxicology strategies for drug discovery: present and future. Chem Res Toxicol 29:473–504.
   PubMed Web of Science ®Google Scholar
• Brown DB. 1976. Systems Analysis and Design for Safety: Safety Systems Engineering.Upper Saddle River (NJ): Prentice Hall.
   Google Scholar
• Burello E, Worth AP. 2015. A rule for designing safer nanomaterials: do not interfere with the cellular redox equilibrium. Nanotoxicology 9:116–17.
   PubMed Web of Science ®Google Scholar
• Costa AL. 2016. Chapter 10 applying safety by molecular design concepts to nanomaterials risk management. In: Murphy F, McAlea EM, Mullins M, eds. Managing Risk in Nanotechnology. Topics in Governance, Assurance and Transfer. Dordrecht: Springer International Publishing, 171–195.
   Google Scholar
• Damalas CA, Eleftherohorinos IG. 2011. Pesticide exposure, safety issues, and risk assessment indicators. Int J Environ Res Pub Health 8:1402–19.
   PubMed Web of Science ®Google Scholar
• Dambach DM, Misner D, Brock M, Fullerton A, Proctor W, Maher J, et al. 2016. Safety lead optimization and candidate identification: integrating new technologies into decision-making. Chem Res Toxicol 29:452–72.
   PubMed Web of Science ®Google Scholar
• Damoiseaux R, George S, Li M, Pokhrel S, Ji Z, France B, et al. 2011. No time to lose–high throughput screening to assess nanomaterial safety. Nanoscale 3:1345–60.
   PubMed Web of Science ®Google Scholar
• Danker T, Möller C. 2014. Early identification of hERG liability in drug discovery programs by automated patch clamp. Front Pharmacol 5:1–11.
   PubMed Web of Science ®Google Scholar
• Donaldson K, Murphy F, Schinwald A, Duffin R, Poland CA. 2011. Identifying the pulmonary hazard of high aspect ratio nanoparticles to enable their safety-by-design. Nanomedicine 6:143–56.
   PubMed Web of Science ®Google Scholar
• Fadeel B, Nel A, Dobson P, Aitken R, Dawson K, Kreyling W, et al. 2011. Chapter 4.9.1 international perspectives from the overseas workshops (US-European Union Workshop). In: Roco MC, Mirkin CA, Hersam MC, eds. Nanotechnology Research Directions for Societal Needs in 2020:146–7. Retrospective and Outlook. Dordrecht: Springer.
   Google Scholar
• Fadeel B. 2013. Nanosafety: towards safer design of nanomedicines. J Intern Med 274:578–80.
   PubMed Web of Science ®Google Scholar
• FDA, 2016. Preventable adverse drug reactions: a focus on drug interactions [webpage]. US food and drug administration. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm. Accessed on 1 November 2016.
   Google Scholar
• Forest V, Leclerc L, Hochepied J-F, Trouvé A, Sarry G, Pourchez J. 2017. Impact of cerium oxide nanoparticles shape on their in vitro cellular toxicity. Toxicol Vitro 38:136–41.
   PubMed Web of Science ®Google Scholar
• Frommeyer G, Eckardt L. 2016. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol 13:36–47.
   PubMed Web of Science ®Google Scholar
• Fröhlich E. 2012. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomed 7:5577–91.
   PubMed Web of Science ®Google Scholar
• Gass S, Cohen JM, Pyrgiotakis G, Sotiriou GA, Pratsinis SE, Demokritou P. 2013. Safer formulation concept for flame-generated engineered nanomaterials. ACS Sustain Chem Eng 1:843–57.
   PubMed Web of Science ®Google Scholar
• George S, Pokhrel S, Xia T, Gilbert B, Ji Z, Schowalter M, et al. 2010. Use of a rapid cytotoxicity screening approach to engineer a safer zinc oxide nanoparticle through iron doping. ACS Nano 4:15–29.
   PubMed Web of Science ®Google Scholar
• Geraci C, Heidel D, Sayes C, Hodson L, Schulte P, Eastlake A, Brenner S. 2015. Perspectives on the design of safer nanomaterials and manufacturing processes. J Nanopart Res 17:1–13.
   Web of Science ®Google Scholar
• Gerloff K, Landesmann B, Worth A, Munn S, Palosaari T, Whelan M. 2016. The adverse outcome pathway approach in nanotoxicology. Comput Toxicol 1:1–9.
   Google Scholar
• Gilbertson LM, Melnikov F, Wehmas LC, Anastas PT, Tanguay RL, Zimmerman JB. 2016. Toward safer multi-walled carbon nanotube design: establishing a statistical model that relates surface charge and embryonic zebrafish mortality. Nanotoxicology 10:10–19.
   PubMed Web of Science ®Google Scholar
• Grieger KD. 2011. Understanding and assessing potential environmental risks of nanomaterials: emerging rools for emerging risks. PhD Thesis, Technical University of Denmark, Kgs. Lyngby, Denmark.
   Google Scholar
• Hansen SF, Baun A. 2015. DPSIR and stakeholder analysis of the use of nanosilver. Nanoethics 9:297–319.
   Web of Science ®Google Scholar
• Hansen SF, Nielsen KN, Knudsen N, Grieger KD, Baun A. 2013. Operationalization and application of ‘early warning signs’ to screen nanomaterials for harmful properties. Environ Sci Process Impacts 15:190–203.
   PubMed Web of Science ®Google Scholar
• Harper SL, Carriere JL, Miller JM, Hutchison JE, Maddux BLS, Tanguay RL. 2011. Systematic evaluation of nanomaterial toxicity: utility of standardized materials and rapid assays. ACS Nano 5:4688–97.
   PubMed Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. 2014. Clinical development success rates for investigational drugs. Nat Biotechnol 32:40–51.
   PubMed Web of Science ®Google Scholar
• Hjorth R, Hansen SF, Jacobs M, Tickner J, Ellenbecker M, Baun A. 2017. The applicability of chemical alternatives assessment for engineered nanomaterials. Integrated Environ Assess Manage 13:177–87. doi: 10.1002/ieam.1762
   PubMed Web of Science ®Google Scholar
• ICON, 2010. Advancing the Eco-Responsible Design and Disposal of Engineered Nanomaterials. Houston (TX): International Council on Nanotechnology (ICON).
   Google Scholar
• Johnston H, Pojana G, Zuin S, Jacobsen NR, Møller P, Loft S, et al. 2013. Engineered nanomaterial risk. Lessons learnt from completed nanotoxicology studies: potential solutions to current and future challenges. Crit Rev Toxicol 43:1–20.
   PubMed Web of Science ®Google Scholar
• Kahru A, Dubourguier H-C. 2010. From ecotoxicology to nanoecotoxicology. Toxicology 269:105–19.
   PubMed Web of Science ®Google Scholar
• Kapuscinski AR, Goodman RM, Hann SD, Jacobs LR, Pullins EE, Johnson CS, et al. 2003. Making'safety first'a reality for biotechnology products. Nat Biotechnol 21:599–601.
   PubMed Web of Science ®Google Scholar
• Karn B, Kuiken T, Otto M. 2009. Nanotechnology and in situ remediation: a review of the benefits and potential risks. Environ Health Perspect 117:1813–31.
   PubMed Web of Science ®Google Scholar
• Kelty CM. 2009. Beyond implications and applications: the story of ‘Safety by Design’. Nanoethics 3:79–96.
   PubMedGoogle Scholar
• Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Dis 3:1–5.
   Web of Science ®Google Scholar
• Lasser KE, Allen PD, Wollhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. 2002. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215–20.
   PubMed Web of Science ®Google Scholar
• Le TC, Yin H, Chen R, Chen Y, Zhao L, Casey PS, et al. 2016. An experimental and computational approach to the development of ZnO nanoparticles that are safe by design. Small 12:3568–77.
   PubMed Web of Science ®Google Scholar
• Leeson P. 2012. Chemical beauty contest. Nature 481:455–6.
   PubMed Web of Science ®Google Scholar
• Lehman SE, Morris AS, Mueller PS, Salem AK, Grassian VH, Larsen SC. 2016. Silica nanoparticle-generated ROS as a predictor of cellular toxicity: mechanistic insights and safety by design. Environ Sci Nano 3:56–66.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv 23:3–25.
   Web of Science ®Google Scholar
• Lynch I. 2014. Compendium of Projects in the European NanoSafety Cluster. 2014 ed. Available at: http://goo.gl/4d6Bqo.
   Google Scholar
• Lynch I. 2015. Compendium of Projects in the European NanoSafety Cluster. 2015 ed. Available at: http://goo.gl/p3Qo50.
   Google Scholar
• Lynch I. 2016. Compendium of Projects in the European NanoSafety Cluster. 2016 ed. Available at: http://www.nanosafetycluster.eu/www.nanosafetycluster.eu/home/european-nanosafety-cluster-compendium.html.
   Google Scholar
• Lynch I, Weiss C, Valsami-Jones E. 2014. A strategy for grouping of nanomaterials based on key physico-chemical descriptors as a basis for safer-by-design NMs. Nano Today 9:266–70.
   Web of Science ®Google Scholar
• Mehta M. 2004. From biotechnology to nanotechnology: what can we learn from earlier technologies? Bull Sci Technol Soc 24:34–9.
   Google Scholar
• Meng H, Xia T, George S, Nel AE. 2009. A predictive toxicological paradigm for the safety assessment of nanomaterials. ACS Nano 3:1620–7.
   PubMed Web of Science ®Google Scholar
• Miller G, Wickson F. 2015. Risk analysis of nanomaterials: exposing nanotechnology’s naked emperor. Rev Policy Res 32:485–512.
   Web of Science ®Google Scholar
• Morose G. 2010. The 5 principles of ‘Design for Safer Nanotechnology’. J Cleaner Product 18:285–9.
   Web of Science ®Google Scholar
• Movia D, Gerard V, Maguire CM, Jain N, Bell AP, Nicolosi V, et al. 2014. A safe-by-design approach to the development of gold nanoboxes as carriers for internalization into cancer cells. Biomaterials 35:2543–57.
   PubMed Web of Science ®Google Scholar
• Möller C. 2010. Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology. Exp Rev Clin Pharmacol 3:321–9.
   PubMedGoogle Scholar
• Naatz H, Lin S, Li R, Jiang W, Ji Z, Chang CH, et al. 2017. Safe-by-design CuO nanoparticles via Fe-doping, Cu–O bond length variation, and biological assessment in cells and zebrafish embryos. ACS Nano 11:501–15.
   PubMed Web of Science ®Google Scholar
• NANoREG, 2015. Comparison on toxicity testing in drug development and in present MNMs safety testing. Deliverable 6.3. Available at: http://www.nanoreg.eu/media-and-downloads/factsheets-of-nanoreg-output/230-deliverabe-6-3-comparison-on-toxicity-testing-in-drug-development-and-in-present-mnms-safety-testing.
   Google Scholar
• National Research Council, 2009. Summary. In: Science and Decisions: Advancing Risk Assessment. Washington, DC: The National Academies Press, 1–14.
   Google Scholar
• Nel AE, Mädler L, Velegol D, Xia T, Hoek EMV, Somasundaran P, et al. 2009. Understanding biophysicochemical interactions at the nano-bio interface. Nature Mater 8:543–57.
   PubMed Web of Science ®Google Scholar
• Nel A, Xia T, Meng H, Wang X, Lin S, Ji Z, Zhang H. 2013. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. Accounts Chem Res 46:607–21.
   PubMed Web of Science ®Google Scholar
• NSC, 2016. European NanoSafety Cluster Compendium [Webpage]. Nanosafety Cluster. Available at: http://www.nanosafetycluster.eu/www.nanosafetycluster.eu/home/european-nanosafety-cluster-compendium.html. Accessed on 1 November 2016.
   Google Scholar
• Polak S, Pugsley MK, Stockbridge N, Garnett C, Wiśniowska B. 2015. Early drug discovery prediction of proarrhythmia potential and its covariates. AAPS J 17:1025–32.
   PubMed Web of Science ®Google Scholar
• Rang HP. 2007. Assessing drug safety. In: Rang HP, ed. Drug Discovery and Development. Technology in Transition. Reprint 2007. Edinburgh: Churchill Livingstone, Elsevier.
   Google Scholar
• Riediker M. 2011. Coordination and collaboration in European research towards healthy and safe nanomaterials. J Phys Conf Ser 304:1.
   Google Scholar
• Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. 2014. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium. Am Heart J 167:292–300.
   PubMed Web of Science ®Google Scholar
• Saleh NB, Aich N, Plazas-Tuttle J, Lead JR, Lowry GV. 2015. Research strategy to determine when novel nanohybrids pose unique environmental risks. Environ Sci Nano 2:11–18.
   Web of Science ®Google Scholar
• Sanguinetti MC, Tristani-Firouzi M. 2006. hERG potassium channels and cardiac arrhythmia. Nature 440:463–9.
   PubMed Web of Science ®Google Scholar
• Sasseville VG, Lane JH, Kadambi VJ, Bouchard P, Lee FW, Balani SK, et al. 2004. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem Biol Interact 150:9–25.
   PubMed Web of Science ®Google Scholar
• Savolainen K, Backman U, Brouwer D, Fadeel B, Fernandes T, Kuhlbusch T, et al. 2013. Nanosafety in Europe 2015–2025: Towards Safe and Sustainable Nanomaterials and Nanotechnology Innovations. Helsinki, Finland: Finnish Institute of Occupational Health, EDITA.
   Google Scholar
• Shah R. 2006. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics 7: 889–908.
   PubMed Web of Science ®Google Scholar
• Shatkin JA, Ong KJ. 2016. Alternative testing strategies for nanomaterials: state of the science and considerations for risk analysis. Risk Anal36:1564–80. doi: 10.1111/risa.12642
   PubMed Web of Science ®Google Scholar
• Sips A, Noorlander C, Lehmann HC, Höhener K. 2015. NANoREG safe-by-design (SbD) concept. Available at: http://www.nanoreg.eu/media-and-downloads/publications/258-nanoreg-safe-by-design-sbd-concept.
   Google Scholar
• Siramshetty VB, Nickel J, Omieczynski C, Gohlke B, Drwal MN, Preissner R. 2015. WITHDRAWN –– a resource for withdrawn and discontinued drugs. Nucleic Acids Res 43:1–7.
   PubMed Web of Science ®Google Scholar
• Skjolding LM, Sørensen SN, Hartmann NB, Hjorth R, Hansen SF, Baun A. 2016. A critical review of aquatic ecotoxicity testing of nanoparticles – the quest for disclosing nanoparticle effects. Angew Chem Int Ed 55:15224–39. doi: 10.1002/anie.201604964
   PubMed Web of Science ®Google Scholar
• Smith GF. 2011. Designing drugs to avoid toxicity. Prog Med Chem 50:1–47. doi: 10.1016/B978-0-12-381290-2.00001-X
   PubMedGoogle Scholar
• Snodin DJ. 2002. An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology. Toxicol Lett 127:161–8.
   PubMed Web of Science ®Google Scholar
• Som C, Nowack B, Krug HF, Wick P. 2013. Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials. Accounts Chem Res 46:863–72.
   PubMed Web of Science ®Google Scholar
• Sotiriou GA, Watson C, Murdaugh KM, Darrah TH, Watson C, Kimberly M, et al. 2014. Engineering safer-by-design silica-coated ZnO nanorods with reduced DNA damage potential. Environ Sci Nano 1:144–53.
   PubMed Web of Science ®Google Scholar
• Stockbridge N, Morganroth J, Shah RR, Garnett C. 2013. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? Drug Safety 36:167–82.
   PubMed Web of Science ®Google Scholar
• Tantra R, Oksel C, Puzyn T, Wang J, Robinson KN, Wang XZ, et al. 2015. Nano(Q)SAR: challenges, pitfalls and perspectives. Nanotoxicology 5390:636–42.
   Web of Science ®Google Scholar
• Tinkle SS. 2010. Maximizing safe design of engineered nanomaterials: the NIH and NIEHS research perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:88–98.
   PubMed Web of Science ®Google Scholar
• Truong L, Simonich MT, Saili KS, Tanguay RL. 2012. Fishing to design inherently safer nanoparticles. In: McGrath P, ed. Zebrafish: Methods for Assessing Drug Safety and Toxicity. Hoboken, NJ: John Wiley & Sons, Inc, 283–93.
   Google Scholar
• US Congress, 1993. Researching Health Risks. OTA-BBS-571. Washington, DC: Office of Technology Assessment.
   Google Scholar
• van Leeuwen CJ. 2007 General introduction. In: van Leeuwen CJ, Vermeire TG, eds. 2nd ed. Risk Assessment of Chemicals: An Introduction. Dordrecht: Springer, 1–36.
   Google Scholar
• von Moos N, Slaveykova VI. 2014. Oxidative stress induced by inorganic nanoparticles in bacteria and aquatic microalgae–state of the art and knowledge gaps. Nanotoxicology 8:605–30.
   PubMed Web of Science ®Google Scholar
• Wake G, Lipscomb S, Holland E, Knowland J. 2004. The effects of manganese doping on UVA absorption and free radical generation of micronised titanium dioxide and its consequences for the photostability of UVA absorbing organic sunscreen components. Photochem Photobiol Sci 3:648–52.
   PubMed Web of Science ®Google Scholar
• Waltz E. 2009. Under wraps: are the crop industry's strong-arm tactics and close-fisted attitude to sharing seeds holding back independent research and undermining public acceptance of transgenic crops? Nat Biotechnol 27:880–3.
   PubMed Web of Science ®Google Scholar
• Wang J, Ruxton T, Labrie CR. 1996. Design for safety of engineering systems with multiple failure state variables. Reliab Eng Syst Safety 50:271–84.
   Web of Science ®Google Scholar
• Xia T, Zhao Y, Sager T, George S, Pokhrel S, Li N, et al. 2011. Decreased dissolution of ZnO by iron doping yields nanoparticles with reduced toxicity in the rodent lung and zebrafish embryos. ACS Nano 5:1223–35.
   PubMed Web of Science ®Google Scholar
• Yan L, Zhao F, Li S, Hu Z, Zhao Y. 2011. Low-toxic and safe nanomaterials by surface-chemical design, carbon nanotubes, fullerenes, metallofullerenes, and graphenes. Nanoscale 3:362–82.
   PubMed Web of Science ®Google Scholar
• Zhang MQ, Wilkinson B. 2007. Drug discovery beyond the ‘rule-of-five’. Curr Opin Biotechnol 18:478–88.
   PubMed Web of Science ®Google Scholar